Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with GARDP

The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and started in association with the World Health Organisation (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP’s programme on sexually transmitted infections (STI), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea. The aim of this project is to fund and support the development of new treatments that address the threat of drug-resistant gonorrhoea in low- and middle- income countries (LMICs). Objectives of the funded activity are to: - develop a new affordable treatment for gonorrhoea, that works on multi-drug resistant cases (trials completed and registration started by 2022) - support the integration of the new treatments into the current Sexually Transmitted Infection management framework by investigating possible antibiotic combinations by 2023 Projects funded through GAMRIF will primarily benefit people in low- and middle-income countries, where the burden of drug-resistant infection is greater.